ALKS vs. RGEN: Which Stock Is the Better Value Option?

Core Viewpoint - Investors in the Medical - Biomedical and Genetics sector should consider Alkermes (ALKS) and Repligen (RGEN) for potential value opportunities, with ALKS currently presenting a more favorable investment case [1] Valuation Metrics - Alkermes has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while Repligen has a Zacks Rank of 4 (Sell) [3] - ALKS has a forward P/E ratio of 16.78, significantly lower than RGEN's forward P/E of 91.29, suggesting that ALKS is undervalued [5] - The PEG ratio for ALKS is 1.37, compared to RGEN's 3.42, indicating that ALKS has a better expected earnings growth relative to its price [5] - ALKS has a P/B ratio of 3.15, while RGEN's P/B ratio is 4.21, further supporting the notion that ALKS is more attractively valued [6] - Based on these valuation metrics, ALKS holds a Value grade of A, whereas RGEN has a Value grade of D, reinforcing the preference for ALKS among value investors [6]